Probing the presence of the ligand-binding haem in cellular nitric oxide receptors

British Journal of Pharmacology

Volumn 153, Issue 7, 2008, Pages 1495-1504

  Roy, B ^a   Mo, E ^a   Vernon, J ^a   Garthwaite, J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

BAY 58 2667; cGMP; Desensitization; Guanylyl cyclase; Haem; HMR 1776; Nitric oxide; ODQ; Platelet

Indexed keywords

4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; CYCLIC GMP; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; HEME; HMR 1766; NITRIC OXIDE; SILDENAFIL; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DESENSITIZATION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME PURIFICATION; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

ANIMALS; BENZOIC ACIDS; BINDING SITES; BLOOD PLATELETS; CATTLE; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; GUANYLATE CYCLASE; HEME; LIGANDS; NITRIC OXIDE; OXIDATION-REDUCTION; PHOSPHORYLATION; RATS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 41649083753     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707687     Document Type: Article

References (39)

1. Bellamy TC, Garthwaite J (2001). Sub-second kinetics of the nitric oxide receptor, soluble guanylyl cyclase, in intact cerebellar cells. J Biol Chem 276: 4287-4292.
2. Bellamy TC, Garthwaite J (2002). Pharmacology of the nitric oxide receptor, soluble guanylyl cyclase, in cerebellar cells. Br J Pharmacol 136: 95-103.
3. Bellamy TC, Wood J, Goodwin DA, Garthwaite J (2000). Rapid desensitization of the nitric oxide receptor, soluble guanylyl cyclase, underlies diversity of cellular cGMP responses. Proc Natl Acad Sci USA 97: 2928-2933.
4. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lapp H, Stasch JP, Burnett Jr JC (2007). Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension 49: 1128-1133.
5. Brandes RP, Kim D, Schmitz-Winnenthal FH, Amidi M, Godecke A, Mulsch A et al. (2000). Increased nitrovasodilator sensitivity in endothelial nitric oxide synthase knockout mice: role of soluble guanylyl cyclase. Hypertension 35: 231-236.
6. Clark DE (1999). Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J Pharm Sci 88: 807-814.
7. Colquhoun D (1998). Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br J Pharmacol 125: 924-947.
8. Craven PA, DeRubertis FR (1978). Restoration of the responsiveness of purified guanylate cyclase to nitrosoguanidine, nitric oxide, and related activators by heme and hemeproteins. Evidence for involvement of the paramagnetic nitrosyl-heme complex in enzyme activation. J Biol Chem 253: 8433-8443.
9. Denninger JW, Marletta MA (1999). Guanylate cyclase and the NO/cGMP signalling pathway. Biochim Biophys Acta 1411: 334-350.
10. Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K, Schmidt H et al. (2006). Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 113: 286-295.
11. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP (2006). NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5: 755-768.
12. Foerster J, Harteneck C, Malkewitz J, Schultz G, Koesling D (1996). A functional heme-binding site of soluble guanylyl cyclase requires intact N-termini of alpha 1 and beta 1 subunits. Eur J Biochem 240: 380-386.
13. Francis SH, Corbin JD (1999). Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action. Crit Rev Clin Lab Sci 36: 275-328.
14. Garthwaite J, Boulton CL (1995). Nitric oxide signaling in the central nervous system. Annu Rev Physiol 57: 683-706.
15. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, Mayer B (1995). Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol 48: 184-188.
16. Garthwaite J (2005). Dynamics of cellular NO-cGMP signaling. Front Biosci 10: 1868-1880.
17. Griffiths C, Wykes V, Bellamy TC, Garthwaite J (2003). A new and simple method for delivering clamped nitric oxide concentrations in the physiological range: application to activation of guanylyl cyclase-coupled nitric oxide receptors. Mol Pharmacol 64: 1349-1356.
18. Gupte SA, Rupawalla T, Phillibert Jr D, Wolin MS (1999). NADPH and heme redox modulate pulmonary artery relaxation and guanylate cyclase activation by NO. Am J Physiol 277: L1124-L1132.
19. Iesaki T, Gupte SA, Wolin MS (1999). A flavoprotein mechanism appears to prevent an oxygen-dependent inhibition of cGMP-associated nitric oxide-elicited relaxation of bovine coronary arteries. Circ Res 85: 1027-1031.
20. Ignarro LJ (1991). Signal transduction mechanisms involving nitric oxide. Biochem Pharmacol 41: 485-490.
21. Ko FN, Wu CC, Kuo SC, Lee FY, Teng CM (1994). YC-1, a novel activator of platelet guanylate cyclase. Blood 84: 4226-4233.
22. Koesling D, Russwurm M, Mergia E, Mullershausen F, Friebe A (2004). Nitric oxide-sensitive guanylyl cyclase: structure and regulation. Neurochem Int 45: 813-819.
23. Kotera J, Grimes KA, Corbin JD, Francis SH (2003). cGMP-dependent protein kinase protects cGMP from hydrolysis by phosphodiesterase-5. Biochem J 372: 419-426.
24. Mergia E, Friebe A, Dangel O, Russwurm M, Koesling D (2006). Spare guanylyl cyclase NO receptors ensure high NO sensitivity in the vascular system. J Clin Invest 116: 1731-1737.
25. Mo E, Amin H, Bianco IH, Garthwaite J (2004). Kinetics of a cellular nitric oxide/cGMP/phosphodiesterase-5 pathway. J Biol Chem 279: 26149-26158.
26. Moncada S, Palmer RM, Higgs EA (1991). Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109-142.
27. Olesen S-P, Drejer J, Axelsson O, Moldt P, Bang L, Nielsen-Kudsk JE et al. (1998). Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase. Br J Pharmacol 123: 299-309.
28. Rand MJ, Li CG (1995). Nitric oxide as a neurotransmitter in peripheral nerves: nature of transmitter and mechanism of transmission. Annu Rev Physiol 57: 659-682.
29. Roy B, Garthwaite J (2006). Nitric oxide activation of guanylyl cyclase in cells revisited. Proc Natl Acad Sci USA 103: 12185-12190.
30. Schindler U, Strobel H, Schonafinger K, Linz W, Lohn M, Martorana PA et al. (2006). Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase. Mol Pharmacol 69: 1260-1268.
31. Schmidt PM, Rothkegel C, Wunder F, Schroder H, Stasch JP (2005). Residues stabilizing the heme moiety of the nitric oxide sensor soluble guanylate cyclase. Eur J Pharmacol 513: 67-74.
32. Schmidt PM, Schramm M, Schroder H, Wunder F, Stasch JP (2004). Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase. J Biol Chem 279: 3025-3032.
33. Schrammel A, Behrends S, Schmidt K, Koesling D, Mayer B (1996). Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol 50: 1-5.
34. Smolenski A, Bachmann C, Reinhard K, Honig-Liedl P, Jarchau T, Hoschuetzky H et al. (1998). Analysis and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation in vitro and in intact cells using a phosphospecific monoclonal antibody. J Biol Chem 273: 20029-20035.
35. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A et al. (2001). NO-independent regulatory site on soluble guanylate cyclase. Nature 410: 212-215.
36. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M et al. (2002). NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 136: 773-783.
37. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, AK HS, Meurer S et al. (2006). Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 116: 2552-2561.
38. Wykes V, Bellamy TC, Garthwaite J (2002). Kinetics of nitric oxide-cyclic GMP signalling in CNS cells and its possible regulation by cyclic GMP. J Neurochem 83: 37-47.
39. Zhao Y, Brandish PE, DiValentin M, Schelvis JP, Babcock GT, Marletta MA (2000). Inhibition of soluble guanylate cyclase by ODQ. Biochemistry 39: 10848-10854.